Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 386 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations MOST POPULAR The link between Down syndrome and childhood leukaemia September 1, 2022 Zanubrutinib’s Approval Improves Targeted Treatment for CLL January 27, 2023 Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... June 17, 2024 Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up August 5, 2025 Load more HOT NEWS Can a Biopsy Make My Cancer Spread? Optimistic targets aren’t enough – this is what we need to... Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... Changing the landscape of children’s cancer treatment
